“The AUC (95% CI) ranged from 0.7092 (0.7090-0.7094) to 0.7468 (0.7465-0.7471) for female and 0.6813 (0.6812-0.6814) to 0.6946 (0.6945-0.6946) for male populations.”
PREVENT is linked with lower statin eligibility in humans (Retrospective assessment using pre-STEMI clinical data; compared with PCE) (8 patients (66.7%) using PREVENT versus 11 (91.7%) using PCE).
“Eleven patients (91.7%) met PCE-based statin eligibility criteria versus eight (66.7%) using PREVENT.”
HumansRetrospective assessment using pre-STEMI clinical data; compared with PCEn = 12
PREVENT is linked with lower estimated 10-year cardiovascular risk in humans (Retrospective assessment using pre-STEMI clinical data; compared with PCE) (Mean estimated risk: 23.4% using PREVENT versus 27.6% using PCE).
“Mean PCE-estimated 10-year risk was 27.6% compared with 23.4% using PREVENT.”
HumansRetrospective assessment using pre-STEMI clinical data; compared with PCEn = 12
PREVENT is linked with lower 10-year ASCVD risk estimates in humans (Black and Latina transgender women with HIV; compared with PCE) (Risk ≥5%: PREVENT versus PCE, 9.5% versus 40.6% with male input; 9.5% versus 17.7% with female input; 8.4% versus 24.0% with female input for hormone users).
“Use of the PREVENT calculator generates lower ASCVD risk estimates than PCE in transgender women with HIV.”
HumansBlack and Latina transgender women with HIV; compared with PCEtransgender womensn = 108
Apolipoprotein B is linked with better PREVENT in humans (added to PREVENT base equations) (continuous NRI 0.67, 95% CI 0.23-1.09).
“Adding apoB to 10-year ASCVD risk estimated by the PREVENT base equations was associated with improved risk reclassification in younger adults (continuous NRI, 0.67; 95% CI, 0.23-1.09)”
PREVENT predicts obstructive coronary artery disease in humans (Patients referred for coronary computed tomography angiography without known ASCVD events) (C-statistic 0.738 (95% CI 0.719-0.756) in women versus 0.708 (95% CI 0.696-0.720) in men; p = 0.006 for the difference).
“The C-statistics of PREVENTTM score for obstructive CAD was 0.738 (95% CI 0.719-0.756) in women and 0.708 (95% CI 0.696-0.720) in men”
HumansPatients referred for coronary computed tomography angiography without known ASCVD eventscoronary arteryn = 17,381
PREVENT predicts cardiovascular disease risk in humans (AUC 0.7092-0.7468 in females vs 0.6813-0.6946 in males).
“The AUC (95% CI) ranged from 0.7092 (0.7090-0.7094) to 0.7468 (0.7465-0.7471) for female and 0.6813 (0.6812-0.6814) to 0.6946 (0.6945-0.6946) for male populations.”
Exercise capacity is associated with PREVENT in humans (beyond demographic base model) (standardized β = -0.079).
“Double product (standardized β = 0.116), HRR at 1 min (standardized β = -0.081), and maximum METs (standardized β = -0.079) were independently associated with risk estimates.”
Humansbeyond demographic base model56.8% malesn = 391
In a subset of 1,015 men, artery stiffness accounted for an estimated 32% of the link between fine-particle pollution and major coronary heart disease or stroke.In a subset of 1,015 men, artery stiffness accounted for an estimated 32% of the link between fine-particle pollution and major coronary heart disease or stroke.
Prescribing for osteoporosis rose immediately by 14.7 percentage points after the reform, but no clear changes emerged in patients’ 12-month outcomes.Prescribing for osteoporosis rose immediately by 14.7 percentage points after the reform, but no clear changes emerged in patients’ 12-month outcomes.